Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...
Mersana falls after early-stage trial data for lead cancer therapy
Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results ...
Mersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...